Novo Nordisk AS (BSP:N1VO34) FFO


BSP:N1VO34 Novo Nordisk AS BSP:N1VO34
74 GF Score
Price R$33.70
GF Value R$93.15
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS FFO?

FFO (Funds from operations) only applies to REITs.

BSP:N1VO34
74GF Score
Novo Nordisk AS BSP:N1VO34
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (BSP:N1VO34) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of R$33.70 is trading 63.8% below its estimated GF Value™ of R$93.15. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for BSP:N1VO34:

  • FFO:
  • GF Value™: R$93.15 vs. price of R$33.70 (63.8% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the BSP:N1VO34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
74GF Score

Get the complete analysis for BSP:N1VO34

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$33.70
Price
R$93.15
GF Value